Clinical Trial Update: A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for rapcabtagene autoleucel in active, refractory systemic lupus erythematosus and lupus nephritis, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis
• Systemic Lupus Erythematosus

Drugs mentioned

• Rapcabtagene Autoleucel

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Lupus Erythematosus, Systemic, Lupus Nephritis | Phase 2 | Status: RECRUITING